Company / Shareholders' Equity
Progyny Shareholders' Equity History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$516.0M
FY2025
5-year range
$251.8M / $553.4M
FY2021-FY2025
Trend
+22.3%
vs FY2024
Sector context
#108 of 166
Health Care
What the data says
At $516M, Progyny's shareholders' equity ranks #108 of 166 in the Health Care sector. Declined from $553M to $516M over the past 2 years.
Based on SEC 10-K filings.
$516M in FY2025 with a 5-year CAGR of +25.3%.
Declined from $553M to $516M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +11.0%
- 5-Year CAGR
- +25.3%
- 10-Year CAGR
- -
Sector benchmark
#108 of 166 in Health CareTop 65% of 166This company $516.0M Sector average $5.3B
▼
-90.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +25.3%, indicating consistent growth.
- In FY2025, shareholders' equity increased 22.3% year-over-year.
- Ranks #108 out of 166 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 3.62 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $516.0M | +22.3% |
| FY2024 | $422.1M | -23.7% |
| FY2023 | $553.4M | +46.8% |
| FY2022 | $377.0M | +49.7% |
| FY2021 | $251.8M | +50.8% |
| FY2020 | $166.9M | +46.1% |
| FY2019 | $114.3M | +220.1% |
| FY2018 | -$95.1M | +2.6% |
| FY2017 | -$97.6M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026